ATE466928T1 - Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram- negativen bakterien - Google Patents

Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram- negativen bakterien

Info

Publication number
ATE466928T1
ATE466928T1 AT00942996T AT00942996T ATE466928T1 AT E466928 T1 ATE466928 T1 AT E466928T1 AT 00942996 T AT00942996 T AT 00942996T AT 00942996 T AT00942996 T AT 00942996T AT E466928 T1 ATE466928 T1 AT E466928T1
Authority
AT
Austria
Prior art keywords
gram
peptidoglycan
negative bacteria
lipid
preparation
Prior art date
Application number
AT00942996T
Other languages
English (en)
Inventor
Benjamin Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE466928T1 publication Critical patent/ATE466928T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00942996T 1999-06-25 2000-06-20 Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram- negativen bakterien ATE466928T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14106199P 1999-06-25 1999-06-25
PCT/US2000/017020 WO2001000790A1 (en) 1999-06-25 2000-06-20 Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria

Publications (1)

Publication Number Publication Date
ATE466928T1 true ATE466928T1 (de) 2010-05-15

Family

ID=22493991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00942996T ATE466928T1 (de) 1999-06-25 2000-06-20 Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram- negativen bakterien

Country Status (15)

Country Link
US (2) US7452715B1 (de)
EP (1) EP1192242B1 (de)
JP (1) JP4660043B2 (de)
KR (1) KR100833364B1 (de)
CN (1) CN1192101C (de)
AT (1) ATE466928T1 (de)
AU (1) AU782566B2 (de)
BR (1) BR0011804B1 (de)
CA (1) CA2370887A1 (de)
DE (1) DE60044352D1 (de)
DK (1) DK1192242T3 (de)
ES (1) ES2343304T3 (de)
IL (1) IL146895A0 (de)
MX (1) MXPA01013253A (de)
WO (1) WO2001000790A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI445545B (zh) 2005-04-08 2014-07-21 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
EP1746103A1 (de) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunktionelle Protein-Anker
JPWO2008105142A1 (ja) * 2007-02-28 2010-06-03 日本電気株式会社 マトリックス溶液
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
TWI409275B (zh) 2009-06-22 2013-09-21 Nat Health Research Institutes 脂質化腫瘤相關抗原及其免疫治療的組成物及方法
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
CN102925447B (zh) * 2012-11-06 2014-04-02 中山大学 肽聚糖结合蛋白BjApextrin1及其基因、生产方法和应用
CN103468704B (zh) * 2012-11-06 2015-01-07 中山大学 肽聚糖结合蛋白BjApextrin2及其基因、生产方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
WO1996040947A1 (en) * 1995-06-07 1996-12-19 Washington University Recombinant bacterial system with environmentally limited viability
DE69815384T2 (de) * 1997-12-05 2003-12-04 Europ Lab Molekularbiolog Neue methode zur klonierung dns unter anwendung des e. coli rece/rect rekombinationssystems

Also Published As

Publication number Publication date
DK1192242T3 (da) 2010-07-26
CN1192101C (zh) 2005-03-09
CA2370887A1 (en) 2001-01-04
AU782566B2 (en) 2005-08-11
BR0011804B1 (pt) 2011-11-01
MXPA01013253A (es) 2002-06-04
JP2003503043A (ja) 2003-01-28
US7741076B2 (en) 2010-06-22
WO2001000790A9 (en) 2009-12-23
ES2343304T3 (es) 2010-07-28
US7452715B1 (en) 2008-11-18
JP4660043B2 (ja) 2011-03-30
AU5753400A (en) 2001-01-31
BR0011804A (pt) 2002-03-19
WO2001000790A1 (en) 2001-01-04
EP1192242B1 (de) 2010-05-05
CN1358227A (zh) 2002-07-10
DE60044352D1 (de) 2010-06-17
US20090060952A1 (en) 2009-03-05
EP1192242A1 (de) 2002-04-03
KR100833364B1 (ko) 2008-05-28
KR20020039270A (ko) 2002-05-25
IL146895A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
DE60044352D1 (de) Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram-negativen bakterien
Reddy et al. Binding between outer membrane proteins of nontypeable Haemophilus influenzae and human nasopharyngeal mucin
Chen et al. Salmonella‐mediated tumor‐targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model
Poole et al. Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine
EP0841941A4 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
Hacker et al. Cloned hemolysin genes from Escherichia coli that cause urinary tract infection determine different levels of toxicity in mice
Byrd et al. Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in nonactivated and interferon gamma-activated human monocytes depending upon its degree of iron saturation. Iron-lactoferrin and nonphysiologic iron chelates reverse monocyte activation against Legionella pneumophila.
Gilleland Jr et al. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection
Chai et al. Two bacteriophages which utilize a new Escherichia coli major outer membrane protein as part of their receptor
IL75277A (en) Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gramnegative bacteria,pharmaceutical formulations composing them and lyphocyte cell lines secreting them
PT2351579T (pt) Vacinas polipeptídicas para proteção ampla contra linhagens meningocócicas hipervirulentas
Judd 125I-peptide mapping of protein III isolated from four strains of Neisseria gonorrhoeae
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
Jacques et al. Adhesin–receptor interactions in Pasteurellaceae
MX9708438A (es) Proteina principal de la membrana externa de moraxella, de alto peso molecular.
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
EP0692031A4 (de) Heterologe antigene in stämmen zur impfung mit lebendzellen
ES8600649A1 (es) Un metodo de producir una forma geneticamente estable de vidrio cholerae
Cohen et al. Mucosal infection with Neisseria gonorrhoeae. Bacterial adaptation and mucosal defenses.
Shiau et al. Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
Kishimoto et al. A new interleukin with pleiotropic activities
FI102189B1 (fi) Menetelmä tippuribakteerin PIA-proteiinin tuottamiseksi ja eristämiseksi
EP0400569B1 (de) Verfahren zur Herstellung eines Antikaries-Impfstoffes aus Streptococcus mutans und Impfzusammensetzung gegen Karies in Form von Nasentropfen
DE69941099D1 (de) Spezifische Nukleinsäuren und Polypeptide aus krankheitserregenden Stämmen von Neisseria

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties